American Lung Association Report Ranks Connecticut 3rd in Nation for Lung Cancer Survival

CTHealthNews.com
November 17, 2026

The American Lung Association’s “State of Lung Cancer” report ranks Connecticut 3rd in the nation for five-year lung cancer survival and 4th for early-stage diagnosis, with survival improving 25% over the past five years.

 

Lung cancer is the leading cause of cancer deaths in Connecticut and the United States. The report puts Connecticut’s five-year survival rate at 38.2%, compared with 31.0% nationally. Early-stage diagnosis stands at 35.2%, up 9% over five years, compared with 29.3% nationally. Connecticut ranks 4th for surgery as a first treatment, at 25% compared with 21.4% nationally, and 5th for lack of treatment, at 16% compared with 20.9%.

 

The report ranks Connecticut 2nd for lung cancer screening, at 35.4% of people at high risk compared with 24.4% nationally, and 3rd for smoking, at 7.5%. Connecticut ranks 27th for new cases, at 53.5 per 100,000 compared with 52.1 nationally, and 29th for radon, at 25.8%. Radon is the second leading cause of lung cancer.

 

Lance Boucher, assistant vice president of state public policy for the American Lung Association, said: “Overall, our report reveals positive news—more people in the U.S. are living longer after a lung cancer diagnosis than ever before, and more people are getting screened for the disease. While these findings give us hope, more must be done to end the burden of this devastating disease on families throughout Connecticut. We need to increase screening rates among those at high risk to catch the disease early when it’s more likely to be curable and improve access to clinical trials and the best lung cancer care.”

 

The report also found that Connecticut requires insurance coverage of comprehensive biomarker testing, which can help identify personalized treatment options. Twenty-four states and Washington, D.C., do not require any coverage.